Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AVADO: Bevacizumab + Docetaxel in HER2- Metastatic Breast Cancer
NCT00333775Phase 3
Key facts
- Status
- Completed
- Start
- Mar 2006
- Primary completion
- Oct 2007
- Countries
- 24
- Sponsor
- Roche
- Modality
- Monoclonal Antibodies
- Drugs
- bevacizumab
- Conditions
- breast cancer
01
Overview
Phase 3, randomised, double-blind trial of bevacizumab in breast cancer (3 arms), sponsored by Roche. Primary endpoint: Progression-free Survival up to 2.5 years. Started Mar 2006; status: completed.
02
Design
3 arms- Study design
- RandomizedDouble-blind
Docetaxel + Placebo
Docetaxel 100 mg/m2 + Placebo q3w
Docetaxel + Bevacizumab 7.5
Docetaxel 100 mg/m2 + Bevacizumab 7.5 mg/kg q3w
Docetaxel + Bevacizumab 15
Docetaxel 100 mg/m2 + Bevacizumab 15.0 mg/kg q3w
03
Who it enrols
Female patients >= 18 years with HER2-negative metastatic or locally recurrent breast cancer suitable for chemotherapy, ECOG 0-1, no prior chemotherapy for metastatic disease.
04
Endpoints
Primary
Progression-free Survival
Secondary
Objective Response Rate
Duration of Response
Time to Treatment Failure
Overall Survival
05
Results
Primary endpoints met
Beyond the preview
Go deeper on NCT00333775.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00333775.